mAb/Ig Fusion Protein

mAb/Ig 融合蛋白

• 批准号: 7691582
• 负责人: Gordon James Freeman
• 金额: $ 31.76万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-04 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7691582
• 关键词: Address; Agonist; Antibodies; Binding; Cells; Chimeric Proteins; Data; Equilibrium; Family; Family member; Generations; Goals; Instruction; Ligands; Mission; Monoclonal Antibodies; Pathway interactions; Production; Reagent; Research Personnel; Role; Signal Transduction; T-Cell Activation; T-Lymphocyte; Time; Variant; cost efficient; crosslink; in vivo; novel; receptor; repository; success

Core B, the Antibody / Ig Fusion Core, will coordinate the use of mAb and Ig fusion proteins for the study of the roles of pathways in the B7:CD28 superfamily in regulating T cell activation and tolerance in vivo, so that these reagents are an easily accessible means of addressing the functions of these important immunoregulatory pathways in vivo. Core B will serve as a critical means by which the Costimulation PPG will achieve its goals of understanding the in vivo functions of the negative second signals provided by pathways in the B7:CD28 family individually, the interactions among these negative signals, and the balance between stimulatory and inhibitory signals transmitted by pathways within the B7:CD28 superfamily. The major goals of Core B, the Antibody / Ig Fusion Core, are to generate novel reagents that facilitate the analysis of the expression and function of B7:CD28 family members and to serve as a repository for and provide existing reagents for the Costimulation PPG Projects and Core C. The generation of novel reagents that induce negative signals is central to the mission of the Costimulation PPG, and Core B provides a critical means by which the PPG will achieve this goal. The availability of large quantities of Ig fusion proteins and mAbs is critical to the success of Projects 1-5. Ig fusion proteins will be used for expression, functional, and signaling studies. Ig fusion proteins, via binding to their ligand, will visualize ligand-expressing cells and may act as agonists via cross-linking and transducing signals through receptors. In addition, Ig fusion proteins may serve as a means to specifically block receptor/ligand interactions. MAbs also will be used to visualize the expression of B7:CD28 family members and as pathway agonists and antagonists. To accomplish these goals, Core B has two aims: Specific Aim 1: To generate novel monoclonal antibodies to study the function and expression of B7:CD28 family members and their polymorphic variants. Specific Aim 2: To serve as a repository and maintain and produce existing and newly generated mAbs and Ig fusion proteins for PPG investigators. The production of these critical reagents by a core not only will be time and cost efficient, but also provide standardized reagents that will facilitate comparison of data by investigators in this PPG. RELEVANCE (See instructions):

核心B，抗体/ IG融合核心，将协调mAb和IG融合蛋白的使用，用于以下研究 B7：CD 28超家族中的通路在体内调节T细胞活化和耐受中的作用， 这些试剂是解决这些重要的功能的容易获得的手段 体内免疫调节途径。核心B将作为共刺激PPG的关键手段 将实现其理解负第二信号的体内功能的目标， B7：CD 28家族中的信号通路，这些负信号之间的相互作用，以及这些负信号之间的平衡。 在B7：CD 28超家族内的通路传递的刺激和抑制信号之间。的 核心B（抗体/ IG融合核心）的主要目标是产生新的试剂， 分析B7：CD 28家族成员的表达和功能，并作为一个知识库， 为共刺激PPG项目和核心C提供现有试剂。新试剂的产生 诱导负信号是共刺激PPG的使命的核心，核心B提供了 这是PPG实现这一目标的关键手段。大量IG融合蛋白的可用性 而mAb对项目1-5的成功至关重要。IG融合蛋白将用于表达、功能性 和信号研究。IG融合蛋白通过与其配体结合，将使表达配体的细胞可视化， 可以通过交联和通过受体转导信号而作为激动剂。此外，IG融合 蛋白质可以作为特异性阻断受体/配体相互作用的手段。MAb还将用于 将B7：CD 28家族成员的表达可视化，并作为途径激动剂和拮抗剂。到 为了实现这些目标，核心B有两个目标： 具体目的1：制备新型单克隆抗体，用于研究B7：CD 28的功能和表达 家族成员及其多态变体。 具体目标2：作为储存库，维护和生产现有和新生成的mAb， 用于PPG研究者的IG融合蛋白。 通过芯生产这些关键试剂不仅将是时间和成本有效的，而且还提供了 标准化试剂，便于研究者在本PPG中进行数据比较。 相关性（参见说明）：